1. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. (January 2022) Authors: Schneeweiss, Andreas; Michel, Laura L.; Möbus, Volker; Tesch, Hans; Klare, Peter; Hahnen, Eric; Denkert, Carsten; Kast, Karin; Pohl-Rescigno, Esther; Hanusch, Claus; Link, Theresa; Untch, Michael; Jackisch, Christian; Blohmer, Jens-Uwe; Fasching, Peter A.; Solbach, Christine; Schmutzler, Rita K.;... Journal: European journal of cancer Issue: Volume 160(2022) Page Start: 100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗